Fluid overload in patients undergoing TAVR: what we can learn from the nephrologists
This study aimed to evaluate whether BIS adds prognostic information in stable patients undergoing transcatheter aortic valve replacement (TAVR).Methods and resultsConsecutive patients scheduled for TAVR underwent BIS in addition to echocardiographic, clinical, and laboratory assessment. On BIS, mild FO was defined as>1.0 L and severe as>3.0 L. Combined HF hospitalization and/or all‐cause death was defined as primary endpoint. Three hundred forty‐four patients (81.5 ± 7.2 years old, 47.4% female) were prospectively included. FO by BIS was associated with clinical congestion signs...
Source: ESC Heart Failure - February 13, 2021 Category: Cardiology Authors: Christian Nitsche, Andreas A. Kammerlander, Matthias Koschutnik, Leah Sinnhuber, Nabila Forutan, Anna Eidenberger, Carolina Don à, Florian Schartmueller, Varius Dannenberg, Max‐Paul Winter, Jolanta Siller‐Matula, Anahit Anvari‐Pirsch, G Tags: Original Research Article Source Type: research
Predicting the clinical course in hypertrophic cardiomyopathy using thallium ‐201 myocardial scintigraphy
This study aimed to evaluate the changes in left ventricular remodelling with time in patients with hypertrophic cardiomyopathy (HCM) using thallium ‐201 myocardial scintigraphy.Methods and resultsForty ‐eight patients with HCM participated in the study. The extent score (ES) and a newly devised index termed the ‘mean count change’ (MCC) were used to evaluate the myocardial perfusion defects. Using the amount of thallium‐201 uptake (TU), MCC (%) was calculated using the following formula: ( last TU − initial TU)∕initial TU × 100. To confirm the site of the lesion, the lef...
Source: ESC Heart Failure - February 12, 2021 Category: Cardiology Authors: Mareomi Hamada, Yuji Shigematsu, Shigeru Nakata, Taishi Kuwahara, Shuntaro Ikeda, Kiyotaka Ohshima, Akiyoshi Ogimoto Tags: Original Research Article Source Type: research
Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction
AbstractAimsBiomarkers reflecting myocardial fibrosis and inflammation have been individually associated with left ventricular hypertrophy (LVH) and diastolic dysfunction (DD). However, the added value of a fibrosis ‐inflammation multimarker approach in a populational setting is yet to be studied. We evaluated the value of a multimarker approach to detect LVH and DD in a large population‐based cohort.Methods and resultsIn a prespecified analysis (BioSe ‐PreIC study) of the 4th visit of the STANISLAS cohort (1705 subjects, 47 ± 14 years, 47.4% men), we evaluated the ability of brain natriuretic p...
Source: ESC Heart Failure - February 12, 2021 Category: Cardiology Authors: Olivier Huttin, Masatake Kobayashi, Jo ão Pedro Ferreira, Stefano Coiro, Erwan Bozec, Christine Selton‐Suty, Laura Filipetti, Zohra Lamiral, Patrick Rossignol, Faiez Zannad, Nicolas Girerd Tags: Short Communication Source Type: research
Sarcopenia in heart failure: a systematic review and meta ‐analysis
AbstractAimsSarcopenia has been found to be frequently associated with co ‐morbidity among patients with heart failure (HF). However, there remain insufficient data to accurately estimate the global prevalence of sarcopenia in HF. Therefore, the purpose of this research was to conduct a systematic review and meta‐analysis to estimate the current overall prevalence of sarcopenia in patients with HF.Methods and resultsWe searched relevant databases for studies published up to 13 July 2020, assessing sarcopenia in vpatients with HF. After careful screening, data of included articles were extracted with a predesigned Excel...
Source: ESC Heart Failure - February 12, 2021 Category: Cardiology Authors: Yan Zhang, Jia Zhang, Wenqing Ni, Xueli Yuan, Hongmin Zhang, Ping Li, Jian Xu, Zhiguang Zhao Tags: Review Source Type: research
Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction
AbstractAimsSeveral different diagnostic parameters can be used to assess left ventricular (LV) longitudinal systolic function, but no studies comparing their predictive value have been conducted. We sought to compare the prognostic value of LV long ‐axis function parameters at rest and exercise using the population with heart failure with preserved ejection fraction (HFpEF).Methods and resultsClinical and biochemical variables were collected at baseline in 201 patients with HFpEF. Echocardiography was performed at rest and immediately after exercise, with measurement of mitral annular plane systolic excursion, systolic ...
Source: ESC Heart Failure - February 11, 2021 Category: Cardiology Authors: Anna Gozdzik, Thomas H. Marwick, Monika Przewlocka ‐Kosmala, Ewa A. Jankowska, Piotr Ponikowski, Wojciech Kosmala Tags: Original Research Article Source Type: research
Type 2 diabetes and heart failure: insights from the global DISCOVER study
ConclusionsIn a large, global cohort of patients with T2D, the majority of incident cases of HF occurred in outpatients and in the absence of known CAD. These findings highlight the need for greater awareness of HF risk in patients with T2D. (Source: ESC Heart Failure)
Source: ESC Heart Failure - February 11, 2021 Category: Cardiology Authors: Suzanne V. Arnold, Kamlesh Khunti, Fabrice Bonnet, Bernard Charbonnel, Hungta Chen, Javier Cid ‐Ruzafa, Andrew Cooper, Peter Fenici, Marilia B. Gomes, Niklas Hammar, Linong Ji, Gabriela Luporini‐Saraiva, Jesús Medina, Antonio Nicolucci, Tags: Short Communication Source Type: research
Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry
ConclusionsThe international QUALIFY Registry suggests that few patients with HFrEF achieve target doses of disease ‐modifying medication, especially older patients and those with co‐morbidity. Quality improvement initiatives are urgently required. (Source: ESC Heart Failure)
Source: ESC Heart Failure - February 11, 2021 Category: Cardiology Authors: Martin R. Cowie, Jakob Sch öpe, Stefan Wagenpfeil, Luigi Tavazzi, Michael Böhm, Piotr Ponikowski, Stefan D. Anker, Gerasimos S. Filippatos, Michel Komajda, QUALIFY Investigators Tags: Original Research Article Source Type: research
The diagnostic and prognostic value of galectin ‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study
AbstractAimsGalectin ‐3 (Gal‐3) predicts long‐term outcome among patients with heart failure (HF) with preserved ejection fraction (HFpEF). The ability of Gal‐3 to diagnose and predict incident HFpEF in a cohort at risk for HFpEF is of particular interest. We aimed to determine the association between Gal‐3 an d clinical manifestations of HFpEF, the relationship between Gal‐3 and all‐cause mortality, or the composite of cardiovascular hospitalization and death.Methods and resultsThe observational Diast ‐CHF study included patients aged 50 to 85 years with ≥1 risk factor for HF (e.g. hypertension, di...
Source: ESC Heart Failure - February 11, 2021 Category: Cardiology Authors: Tobias Daniel Trippel, Meinhard Mende, Hans ‐Dirk Düngen, Djawid Hashemi, Johannes Petutschnigg, Kathleen Nolte, Christoph Hermann‐Lingen, Lutz Binder, Gerd Hasenfuss, Burkert Pieske, Rolf Wachter, Frank Edelmann Tags: Original Research Article Source Type: research
Pump thrombosis and dynamic outflow graft compression: complications in left ventricular assist device therapy
AbstractOver the past decade, left ventricular assist device (VAD) therapy has become more prevalent and increasingly safe. Severe complications, such as VAD pump thrombosis and outflow graft obstruction, are rare, yet still associated with high morbidity and mortality. Clinical presentation, VAD alarm and log files, laboratory analysis, and non ‐invasive cardiac imaging are crucial for establishing the correct diagnosis and determining clinical management. Early intervention is critical to prevent adverse cardiac remodelling or VAD pump failure. (Source: ESC Heart Failure)
Source: ESC Heart Failure - February 10, 2021 Category: Cardiology Authors: Stephan Dobner, Christoph Gr äni, Beate Hugi‐Mayr, Maks Mihalj, Daniel Rhyner, Monika Wieser, Michele Martinelli, Lukas Hunziker, David Reineke Tags: Case Report Source Type: research
A novel echocardiographic method for estimation of pulmonary artery wedge pressure and pulmonary vascular resistance
This study aimed to evaluate a novel echocardiographic algorithm for quantitative estimation of pulmonary artery wedge pressure (PAWP) and pulmonary vascular resistance (PVR) in patients with heart failure and pulmonary hypertension (PH) scheduled to right heart catheterization (RHC).Methods and resultsIn this monocentric study, 795 consecutive patients (427 men; age 68.4 ± 12.1 years) undergoing echocardiography and RHC were evaluated. Multiple regression analysis was performed to identify echocardiographic predictors of PAWP and PVR measured by RHC in the derivation group (the first 200 patients). ...
Source: ESC Heart Failure - February 10, 2021 Category: Cardiology Authors: Vladislav Chubuchny, Nicola Riccardo Pugliese, Claudia Taddei, Elisa Poggianti, Valentina Spini, Andrea Barison, Bruno Formichi, Edoardo Air ò, Carolina Bauleo, Renato Prediletto, Luigi Emilio Pastormerlo, Michele Coceani, Marco Ciardetti, C Tags: Original Research Article Source Type: research
Impact of telemedicine on the management of heart failure patients during coronavirus disease 2019 pandemic
ConclusionsIn the light of an increase in telemedical management of this cohort of HF patients, we were able to maintain a low rate of admissions due to HF decompensation, without an increment in mortality. Regarding these results, we encourage the incremental use of telemedicine in HF patients in the context of this or future pandemics and also in situations in which physical consultation might not be possible due to logistic issues. (Source: ESC Heart Failure)
Source: ESC Heart Failure - February 9, 2021 Category: Cardiology Authors: Marta Afonso Nogueira, Fernanda Ferreira, Ana Filipa Raposo, Lurdes M ónica, Sara Simões Dias, Rafael Vasconcellos, Gonçalo Proença Tags: Original Research Article Source Type: research
A New Requirement for Publication: Access to Effective Drugs for Ethical Reasons, The Example of Heart Failure
AbstractThe past decade has witnessed the publication of many trials in the field of heart failure, several of which have demonstrated that new drugs could potentially reduce major cardiac events and sometimes even decrease total mortality. Most medical practitioners have experimented with withdrawal of the drug under investigation, having no knowledge of what the patient had received, consistent with a blinded design. In some such cases, the patient's clinical status may be rapidly compromised after withdrawal, suggesting (i) that the patient had been receiving the active drug and (ii) that the drug under investigation mi...
Source: ESC Heart Failure - February 9, 2021 Category: Cardiology Authors: Fran çois Roubille, Nicolas Lamblin Tags: Perspective Source Type: research
Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis
AbstractAimsThe mortality in cardiogenic shock (CS) is high. The role of specific mechanical circulatory support (MCS) systems is unclear. We aimed to compare patients receiving Impella versus ECLS (extracorporal life support) with regard to baseline characteristics, feasibility, and outcomes in CS.Methods and resultsThis is a retrospective cohort study including CS patients over 18 years with a complete follow‐up of the primary endpoint and available baseline lactate level, receiving haemodynamic support either by Impella 2.5 or ECLS from two European registries. The decision for device implementation was made at ...
Source: ESC Heart Failure - February 9, 2021 Category: Cardiology Authors: Bernhard Wernly, Mina Karami, Annemarie E. Engstr öm, Stephan Windecker, Lukas Hunziker, Thomas F. Lüscher, Jose P. Henriques, Markus W. Ferrari, Stephan Binnebößel, Maryna Masyuk, David Niederseer, Peter Abel, Georg Fuernau, Marcus Franz Tags: Original Research Article Source Type: research
Characteristics and prognostic value of right ventricular (dys)function in patients with non ‐ischaemic dilated cardiomyopathy assessed with cardiac magnetic resonance imaging
This study sought to determine the correlation of RV dysfunction with several cardiac magnetic resonance (CMR) imaging characteristics in patients with DCM, and the prognostic value of R V dysfunction on all‐cause mortality and ventricular arrhythmias (VA) was evaluated.Methods and resultsConsecutive patients with DCM and left ventricular (LV) dysfunction (ejection fraction
Source: ESC Heart Failure - February 9, 2021 Category: Cardiology Authors: Marthe A.J. Becker, Anne ‐Lotte C.J. Lingen, Marc Wubben, Peter M. Ven, Albert C. Rossum, Jan H. Cornel, Cornelis P. Allaart, Tjeerd Germans Tags: Original Research Article Source Type: research
Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction
AbstractAimsCongestive heart failure (CHF) and impaired renal function are two often co ‐existing medical conditions and associated with adverse cardiovascular outcome. The aim of the current study was to assess renal and intraglomerular haemodynamics by constant infusion input clearance technique in subjects with CHF.Methods and resultsThe group of subjects with CHF consisted of 27 individuals with HFpEF and 27 individuals with HFrEF and were compared with 31 healthy controls. Subjects underwent renal clearance examination to measure glomerular filtration rate (GFR) and renal blood and plasma flow (RBF and RPF) and to c...
Source: ESC Heart Failure - February 9, 2021 Category: Cardiology Authors: Susanne Jung, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Dennis Kannenkeril, Tizia Schuster, Christian Ott, Stephan Achenbach, Roland E. Schmieder Tags: Original Research Article Source Type: research
Cardio ‐microcurrent device for chronic heart failure: first‐in‐human clinical study
AbstractAimsMost devices for treating ambulatory Class II and III heart failure are linked to electrical pulses. However, a steady electric potential gradient is also necessary for appropriate myocardial performance and may be disturbed by structural heart diseases. We investigated whether chronic application of electrical microcurrent to the heart is feasible and safe and improves cardiac performance. The results of this study should provide guidance for the design of a two ‐arm, randomized, controlled Phase II trial.Methods and resultsThis single ‐arm, non‐randomized pilot study involved 10 patients (9 men; mean ag...
Source: ESC Heart Failure - February 9, 2021 Category: Cardiology Authors: Dragana Kosevic, Dominik Wiedemann, Petar Vukovic, Velibor Ristic, Julia Riebandt, Una Radak, Kersten Brandes, Peter Goettel, Hans ‐Dirk Duengen, Elvis Tahirovic, Tatjana Kottmann, Hans Werner Voss, Marija Zdravkovic, Svetozar Putnik, Jan Tags: Original Research Article Source Type: research
The impact of frailty according to Clinical Frailty Scale on clinical outcome in patients with heart failure
AbstractAimsThere is currently no gold standard in evaluating frailty in patients with heart failure (HF), and the prognostic value of frailty according to the Canadian Study of Health and Aging Clinical Frailty Scale (CFS) on mortality in patients with HF is still unknown.Methods and resultsAmong consecutive 596 patients after their discharge from HF in Kokura Memorial Hospital (Kitakyushu, Japan) during 2015, their frailty at discharge was assessed according to CFS. Patients were classified into three groups: low (N = 232, 38.9%), intermediate (N = 230, 38.6%), and high (N = 134, 22.5%). The...
Source: ESC Heart Failure - February 6, 2021 Category: Cardiology Authors: Kenji Kanenawa, Akihiro Isotani, Kyohei Yamaji, Miho Nakamura, Yuichi Tanaka, Kaoru Hirose ‐Inui, Shimpei Fujioka, Shintaro Mori, Mariko Yano, Shinya Ito, Takashi Morinaga, Masato Fukunaga, Makoto Hyodo, Kenji Ando Tags: Original Research Article Source Type: research
Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome
AbstractAimsWe aimed to determine whether in children with dilated cardiomyopathy repeated measurement of known risk factors for death or heart transplantation (HTx) during disease progression can identify children at the highest risk for adverse outcome.Methods and resultsOf 137 children we included in a prospective cohort, 36 (26%) reached the study endpoint (SE: all ‐cause death or HTx), 15 (11%) died at a median of 0.09 years [inter‐quartile range (IQR) 0.03–0.7] after diagnosis, and 21 (15%) underwent HTx at a median of 2.9 years [IQR 0.8–6.1] after diagnosis. Median follow‐up was 2.1 years...
Source: ESC Heart Failure - February 6, 2021 Category: Cardiology Authors: Marijke Meulen, Susanna Boer, Gideon J. Marchie Sarvaas, Nico Blom, Arend D.J. Harkel, Hans M.P.J. Breur, Lukas A.J. Rammeloo, Ronald Tanke, Ad J.J.C. Bogers, Willem A. Helbing, Eric Boersma, Michiel Dalinghaus Tags: Original Research Article Source Type: research
Prevalence of low health literacy levels in decompensated heart failure compared with acute myocardial infarction patients
AbstractAimsHealth literacy (HL) is a health determinant in cardiovascular diseases as the active participation of patients is essential for optimizing self ‐management of these conditions. We aimed to estimate the prevalence of low HL level in patients hospitalized for acute myocardial infarction (AMI) or acute decompensated heart failure (ADHF) and explore low HL determinants.Methods and resultsA prospective cross ‐sectional study was performed in three cardiology units. HL level was assessed using Brief Health Literacy Screen (BHLS) and categorized as low or adequate. Dimensions of HL were assessed with the Health L...
Source: ESC Heart Failure - February 5, 2021 Category: Cardiology Authors: Ad èle Perrin, Gergis Abdalla, Marie Viprey, François Delahaye, Nathan Mewton, Michel Ovize, Laurent Sebbag, Thomas Bochaton, Alexandra L. Dima, Estelle Bravant, Anne‐Marie Schott, Julie Haesebaert Tags: Original Research Article Source Type: research
Meta ‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
(Source: ESC Heart Failure)
Source: ESC Heart Failure - February 5, 2021 Category: Cardiology Authors: Mei Qiu, Liang ‐Liang Ding, Ze‐Lin Zhan, Hai‐Rong Zhou Tags: Letter to the Editor Source Type: research
Myocardial deformation assessed among heart failure entities by cardiovascular magnetic resonance imaging
AbstractAimsAlthough heart failure (HF) is a leading cause for hospitalization and mortality, normalized and comparable non ‐invasive assessment of haemodynamics and myocardial action remains limited. Moreover, myocardial deformation has not been compared between the guideline‐defined HF entities. The distribution of affected and impaired segments within the contracting left ventricular (LV) myocardium have also not been compared. Therefore, we assessed myocardial function impairment by strain in patients with HF and control subjects by magnetic resonance imaging after clinically phenotyping these patients.Methods and ...
Source: ESC Heart Failure - February 4, 2021 Category: Cardiology Authors: Djawid Hashemi, Laura Motzkus, Moritz Blum, Robin Kraft, Radu Tanacli, Elvis Tahirovic, Patrick Doeblin, Victoria Zieschang, S. Mahsa Zamani, Marcus Kelm, Titus Kuehne, Burkert Pieske, Alessio Alogna, Frank Edelmann, Hans ‐Dirk Duengen, S Tags: Original Research Article Source Type: research
Prognostic impact of elevated fatty acid ‐binding protein 1 in patients with heart failure
AbstractAimsFew biomarkers to evaluate pathophysiological changes in extra ‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive biomarker for liver injury. However, little is known about the potential role of FABP1 as a biomarker for HF.Methods and resultsMeasurements of serum FABP1 and echocardiography were performed in subjects with compensated HF (n = 162) and control subjects without HF (n = 20). Patients were prospect...
Source: ESC Heart Failure - February 4, 2021 Category: Cardiology Authors: Kazuki Kagami, Hiroaki Sunaga, Hidemi Sorimachi, Tomonari Harada, Kuniko Yoshida, Toshimitsu Kato, Koji Kurosawa, Ryo Kawakami, Norimichi Koitabashi, Tatsuya Iso, Takeshi Adachi, Masahiko Kurabayashi, Masaru Obokata Tags: Original Research Article Source Type: research
Eligibility for subcutaneous implantable cardioverter ‐defibrillator in adults with congenital heart disease
ConclusionsPatients with ACHD show satisfactory eligibility rates (83%) for S ‐ICD implantation utilizing the automated screening test, including patients with CHD of high complexity. S‐ICD therapy should be considered with caution in ACHD patients with a QRS duration ≥148 ms and/or need for ventricular pacing. (Source: ESC Heart Failure)
Source: ESC Heart Failure - February 4, 2021 Category: Cardiology Authors: Christos Zormpas, Ann Sophie Silber ‐Peest, Jörg Eiringhaus, Henrike A.K. Hillmann, Stephan Hohmann, Johanna Müller‐Leisse, Mechthild Westhoff‐Bleck, Christian Veltmann, David Duncker Tags: Original Research Article Source Type: research
Non ‐alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues
In conclusion, identifying HF patients at risk of NAFLD is a critically important issue. As soon as NAFLD is confirmed and its severity determined, patients should be proposed a management focused on symptoms and co‐morbidities. (Source: ESC Heart Failure)
Source: ESC Heart Failure - February 3, 2021 Category: Cardiology Authors: Romain Itier, Maeva Guillaume, Jean ‐Etienne Ricci, François Roubille, Nicolas Delarche, François Picard, Michel Galinier, Jérôme Roncalli Tags: Review Source Type: research
Doxorubicin ‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol
AbstractAimsOur objectives were to validate a murine model of chronic cardiotoxicity induced by Doxorubicin (Dox) and Trastuzumab (Trast) and to test the potential cardio ‐protective effect of metoprolol.Methods and resultsMale C57Bl6 mice were intraperitoneally injected during 2 weeks with Dox (24 mg/kg) or saline, and then with Trast (10 mg/kg) or saline for two more weeks. Half of the mice received metoprolol (100 mg/kg). Cardiotoxicity was defined by a decline in left ventricular ejection fraction (LVEF) ≥ 10 points. At Day 42, Dox + Trast‐treated mice exhib ited a 13‐p...
Source: ESC Heart Failure - February 2, 2021 Category: Cardiology Authors: Martin Nicol, Malha Sadoune, Evelyne Polidano, Jean Marie Launay, Jane Lise Samuel, Feriel Azibani, Alain Cohen ‐Solal Tags: Original Research Article Source Type: research
The diagnosis of a giant cardiac malignant lymphoma in the right ventricle: a case report
We reported a 71 ‐year‐old male patient who was repeatedly diagnosed of pulmonary infection, suspected lung tumour, and Kimura disease in other hospital due to cough, expectoration, and dyspnoea. Later on, the patient visited our hospital due to heart failure and epistaxis. Transthoracic echocardiogram confirmed the presence of a space‐occupying lesion in the right heart, cardiac magnetic resonance imaging preliminarily determined the nature of this lesion, finally,18F ‐fluorodeoxyglucose positron‐emission tomography/computed tomography, and nasal mass biopsy confirmed the diagnosis of cardiac malignant lymphoma,...
Source: ESC Heart Failure - February 2, 2021 Category: Cardiology Authors: Jiafeng Yu, Xin Zhao, Yingfeng Liu, Qingwei Yan, Fei Miao Tags: Case Report Source Type: research
An aetiology ‐based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH‐HF) trial
AbstractAimsThe aim of our study was to analyse the benefits of a 9 week hybrid comprehensive telerehabilitation (HCTR) programme in heart failure (HF) patients according to aetiology, as a subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH‐HF) trial.Methods and resultsOverall, 555 (65.3%) patients with ischaemic (IS) and 295 (34.7%) patients with non ‐ischaemic (NIS) HF aetiology were randomized. There were no differences between the effect of HCTR and usual care (UC) on the primary outcome of number of days alive and out of the hospital in 26 months from the time of randomization in e...
Source: ESC Heart Failure - February 2, 2021 Category: Cardiology Authors: Dominika Szalewska, Renata G łówczyńska, Ryszard Piotrowicz, Ilona Kowalik, Michael J. Pencina, Grzegorz Opolski, Wojciech Zaręba, Maciej Banach, Piotr Orzechowski, Sławomir Pluta, Robert Irzmański, Zbigniew Kalarus, Ewa Piotrowicz Tags: Original Research Article Source Type: research
INTERVENE ‐HF: feasibility study of individualized, risk stratification‐based, medication intervention in patients with heart failure with reduced ejection fraction
ConclusionsThe Intervene ‐HF study supports the feasibility of testing, in a large randomized clinical trial, an ambulatory medication intervention strategy that is physician‐directed, CHFN‐implemented, and based on individualized device risk stratification. (Source: ESC Heart Failure)
Source: ESC Heart Failure - February 2, 2021 Category: Cardiology Authors: Michael R. Zile, Maria Rosa R. Costanzo, Ekaterina M. Ippolito, Yan Zhang, Russell Stapleton, Ashish Sadhu, Javier Jimenez, Joe Hobbs, Vinod Sharma, Eduardo N. Warman, Lindsay Streeter, Javed Butler Tags: Original Research Article Source Type: research
Mortality risk prediction in elderly patients with cardiogenic shock: results from the CardShock study
This study aimed to assess the utility of contemporary clinical risk scores and explore the ability of two biomarkers [growth differentiation factor ‐15 (GDF‐15) and soluble ST2 (sST2)] to improve risk prediction in elderly patients with cardiogenic shock.Methods and resultsPatients (n = 219) from the multicentre CardShock study were grouped according to age (elderly ≥75 years and younger). Characteristics, management, and outcome between the groups were compared. The ability of the CardShock risk score and the IABP‐SHOCK II score to predict in‐hospital mortality and the additional value of GDF‐...
Source: ESC Heart Failure - February 1, 2021 Category: Cardiology Authors: Mari Hongisto, Johan Lassus, Tuukka Tarvasm äki, Alessandro Sionis, Jordi San Roselló, Heli Tolppanen, Anu Kataja, Toni Jäntti, Tuija Sabell, Matias Greve Lindholm, Marek Banaszewski, Jose Silva Cardoso, John Parissis, Salvatore Di Somma, Tags: Original Research Article Source Type: research
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction
AbstractAimsSacubitril/valsartan combines renin –angiotensin–aldosterone system inhibition with amplification of natriuretic peptides. In addition to well‐described effects, natriuretic peptides exert direct effects on pulmonary vasculature. The effect of sacubitril/valsartan on pulmonary artery pressure (PAP) has not been fully defined.Methods and resultsThis was a retrospective case ‐series of PAP changes following transition from angiotensin‐converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) to sacubitril/valsartan in patients with heart failure reduced ejection fraction and a pre...
Source: ESC Heart Failure - February 1, 2021 Category: Cardiology Authors: Jeffrey S. Tran, Ofer Havakuk, Jennifer Mcleod, Jennifer Hwang, Hoi Yan Kwong, David Shavelle, Michael R. Zile, Uri Elkayam, Michael W. Fong, Luanda P. Grazette Tags: Short Communication Source Type: research
Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction
AbstractAimsWhether and how iron deficiency (ID) impacts patients with heart failure (HF) with preserved ejection fraction (HFpEF) remain unclear. The aim of our study was to investigate the impact of ID on functional status, exercise capacity, and prognosis in HFpEF.Methods and resultsThe study population consisted of 300 HFpEF patients. ID was defined as serum ferritin
Source: ESC Heart Failure - February 1, 2021 Category: Cardiology Authors: Arantxa Barandiar án Aizpurua, Sandra Sanders‐van Wijk, Hans‐Peter Brunner‐La Rocca, Michiel T.H.M. Henkens, Jerremy Weerts, Mireille H.A. Spanjers, Christian Knackstedt, Vanessa P.M. Empel Tags: Original Research Article Source Type: research
Myotonic dystrophy patients: More data about cardiac and neurologic findings would be useful
(Source: ESC Heart Failure)
Source: ESC Heart Failure - February 1, 2021 Category: Cardiology Authors: Claudia St öllberger, Josef Finsterer Tags: Letter to the Editor Source Type: research
Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction
This study aimed at evaluating cardiac expression levels of key genes of interest in human biopsy samples from patients affected with HFrEF and HFpEF in order to possibly point out distinct phenotypes.Methods and resultsTotal RNA was extracted from left ventricular cardiac biopsies collected from stable patients with HFrEF (n = 6) and HFpEF (n = 7) and healthy subjects (n = 9) undergoing elective cardiac surgery for valvular replacement, mitral valvuloplasty, aortic surgery, or coronary artery bypass. Real‐time PCR was performed to evaluate the mRNA expression levels of genes involved in som...
Source: ESC Heart Failure - January 29, 2021 Category: Cardiology Authors: Roberta D'Assante, Michele Arcopinto, Giuseppe Rengo, Andrea Salzano, Marion Walser, Giuseppina Gambino, Maria Gaia Monti, Leonardo Bencivenga, Alberto M. Marra, David N. Åberg, Carlo De Vincentiis, Andrea Ballotta, Eduardo Bossone, Jörgen Tags: Short Communication Source Type: research
The effect of three major co ‐morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction
AbstractAimsDiabetes mellitus, chronic obstructive pulmonary disease, and chronic kidney disease are prevalent in patients with heart failure with reduced ejection fraction (HFrEF). We have analysed the impact of co ‐morbidities on quality of life (QoL) and outcome.Methods and resultsA total of 397 patients (58.8 ± 11.0 years, 73.6% with New York Heart Association functional class ≥3) with stable advanced HFrEF were followed for a median of 1106 (inter‐quartile range 379–2606) days, and 68% of patients (270 patients) experienced an adverse outcome (death, urgent heart transplantation, an...
Source: ESC Heart Failure - January 29, 2021 Category: Cardiology Authors: Jan Benes, Martin Kotrc, Petr Jarolim, Lenka Hoskova, Marketa Hegarova, Zora Dorazilova, Mariana Podzimkova, Jana Binova, Marianna Lukasova, Ivan Malek, Janka Franekova, Antonin Jabor, Josef Kautzner, Vojtech Melenovsky Tags: Original Research Article Source Type: research
Endothelial NADPH oxidase 4 protects against angiotensin II ‐induced cardiac fibrosis and inflammation
AbstractAimsEndothelial activation and inflammatory cell infiltration have important roles in the development of cardiac fibrosis induced by renin –angiotensin system activation. NADPH oxidases (Nox proteins) are expressed in endothelial cells (ECs) and alter their function. Previous studies indicated that Nox2 in ECs contributes to angiotensin II (AngII)‐induced cardiac fibrosis. However, the effects of EC Nox4 on cardiac fibrosis are unk nown.Methods and resultsTransgenic (TG) mice overexpressing endothelial ‐restricted Nox4 were studied alongside wild‐type (WT) littermates as controls. At baseline, Nox4 TG m...
Source: ESC Heart Failure - January 29, 2021 Category: Cardiology Authors: Minshu Wang, Colin E. Murdoch, Alison C. Brewer, Aleksandar Ivetic, Paul Evans, Ajay M. Shah, Min Zhang Tags: Original Research Article Source Type: research
Risk of in ‐hospital life‐threatening ventricular arrhythmia or death after ST‐elevation myocardial infarction vs. the Takotsubo syndrome
ConclusionsIn a predominantly female age ‐matched and sex‐matched cohort of patients with TS, anterior STEMI, and non‐anterior STEMI, the adjusted risk of in‐hospital LTVA or death was considerably lower in TS compared with STEMI, despite similar or greater risk of acute heart failure and similar risk of cardiogenic shock. (Source: ESC Heart Failure)
Source: ESC Heart Failure - January 29, 2021 Category: Cardiology Authors: Rickard Zeijlon, Jasmina Chamat, Israa Enabtawi, Sandeep Jha, Mohammed Munir Mohammed, Johan W ågerman, Vina Le, Aaron Shekka Espinosa, Erik Nyman, Elmir Omerovic, Björn Redfors Tags: Original Research Article Source Type: research
Usefulness of CHADS2, R2CHADS2, and CHA2DS2 ‐VASc scores for predicting incident atrial fibrillation in heart failure with preserved ejection fraction patients
ConclusionsOur data first suggest that the CHADS2, R2CHADS2, and CHA2DS2 ‐VASc scores could predict the risk of incident AF in HFpEF patients with modest predictive abilities. (Source: ESC Heart Failure)
Source: ESC Heart Failure - January 28, 2021 Category: Cardiology Authors: Yuzhong Wu, Zengshuo Xie, Weihao Liang, Ruicong Xue, Zexuan Wu, Dexi Wu, Jiangui He, Wengen Zhu, Chen Liu Tags: Original Research Article Source Type: research
Beyond the stethoscope: managing ambulatory heart failure during the COVID ‐19 pandemic
AbstractThere have been nearly 70 million cases of COVID ‐19 worldwide, with over 1.5 million deaths at the time of this publication. This global pandemic has mandated dramatic changes in healthcare delivery with a particular focus on social distancing in order to reduce viral transmission. Heart failure patients are among the highest utilizers of healt h care and are at increased risk for COVID‐related vulnerabilities. Effectively managing this complex and resource‐intensive patient population from a distance presents new and unique challenges. Here, we review relevant data on telemedicine and remote monitoring stra...
Source: ESC Heart Failure - January 28, 2021 Category: Cardiology Authors: Andrew S. Oseran, Maxwell E. Afari, Conor D. Barrett, Gregory D. Lewis, Sunu S. Thomas Tags: Review Source Type: research
Development and implementation of a remote patient monitoring program for heart failure: a single ‐centre experience
This study describes the implementation and outcomes of a dua l platform RPM program for HF at a single centre.Methods and resultsAn RPM program was developed to include two platforms (e.g. CardioMEMS ™ HF System and HeartLogic™ HF Diagnostic). To examine changes within each participant over time, study‐related outcomes including total hospitalizations (TH), total length of stay (TLOS), cardiac hospitalizations (CH), cardiac LOS (CLOS), and cardiac‐related emergency department (ED) visits were compared in two timeframes: 12 months pre‐enrolment and post‐enrolment into RPM. For 141 participants enro...
Source: ESC Heart Failure - January 28, 2021 Category: Cardiology Authors: Bryana N. Baginski, Kaileigh A. Byrne, Dev G. Vaz, Regina Barber, Dawn Blackhurst, Thomas P. Tibbett, Jason L. Guichard Tags: Original Research Article Source Type: research
High ‐protein vs. standard‐protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro‐HEART trial
AbstractAimsThe intermediate ‐term effects of dietary protein on cardiometabolic risk factors in overweight and obese patients with heart failure and diabetes mellitus are unknown. We compared the effect of two calorie‐restricted diets on cardiometabolic risk factors in this population.Methods and resultsIn this randomized controlled study, 76 overweight and obese (mean weight, 107.8 ± 20.8 kg) patients aged 57.7 ± 9.7 years, 72.4% male, were randomized to a high‐protein (30% protein, 40% carbohydrates, and 30% fat) or standard‐protein diet (15% protein, 55% carbohydrate...
Source: ESC Heart Failure - January 27, 2021 Category: Cardiology Authors: Lorraine S. Evangelista, Mini M. Jose, Hanaa Sallam, Hani Serag, George Golovko, Kamil Khanipov, Michele A. Hamilton, Gregg C. Fonarow Tags: Original Research Article Source Type: research
Worsening of heart failure by coronavirus disease 2019 is associated with high mortality
AbstractAimsPatients with advanced heart failure (HF) with reduced left ventricular ejection fraction (HFrEF) and concurrent coronavirus disease 2019 (COVID ‐19) might have a higher risk of severe events.Methods and resultsWe retrospectively studied 16 patients with advanced HFrEF who developed COVID ‐19 between 1 March and 29 May 2020. Follow‐up lasted until 30 September. Ten patients previously hospitalized with decompensated HFrEF were infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) during hospitalization. Six patients undergoing ambulatory care at initiatio n of COVID‐19 symptoms ...
Source: ESC Heart Failure - January 27, 2021 Category: Cardiology Authors: Edimar Alcides Bocchi, Ivna Girard Cunha Vieira Lima, Bruno Biselli, Vera Maria Cury Salemi, Silvia Moreira Ayub Ferreira, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Ranna Santos Pessoa, Francisco Akira Malta Cardoso, Mariana Vieira de Olivei Tags: Original Research Article Source Type: research
Extracorporeal membrane oxygenation ‐assisted emergency percutaneous treatment of left ventricular assist device graft occlusion
AbstractEnd ‐stage heart failure is more often treated with Implantable left ventricular assist device (LVAD), even if the prolonged use may increase the risk of complications. In this case, a 51‐year‐old male patient presented to our emergency department showing acute heart failure signs and symptoms and a dramatic reduction of LVAD flow. Laboratory tests ruled out significant haemolysis, usually associated with pump thrombosis. The echocardiogram and the computed tomography were not able to clarify the correct diagnosis. We immediately placed a veno‐arterial extracorporeal membrane oxygenation, followed by a sele...
Source: ESC Heart Failure - January 26, 2021 Category: Cardiology Authors: Rocco Edoardo Stio, Andrea Montalto, Mariano Feccia, Alfredo Intorcia, Vitaliano Buffa, Vincenzo Cesario, Giulia Petroni, Francesco De Felice, Francesco Musumeci Tags: Case Report Source Type: research
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
AbstractAimsSacubitril/valsartan (sac/val) has shown superior effect compared with blockade of the renin –angiotensin–aldosterone system in heart failure with reduced ejection fraction. We aimed to investigate effects of sac/val compared with valsartan in a pressure overload model of heart failure with preserved ejection fraction (HFpEF).Methods and resultsSprague –Dawley rats underwent aortic banding or sham (n = 16) surgery and were randomized to sac/val (n = 28), valsartan (n = 29), or vehicle (n = 26) treatment for 8 weeks. Sac/val reduced left ventricular ...
Source: ESC Heart Failure - January 26, 2021 Category: Cardiology Authors: Einar Sjaastad Nord én, Bård Andre Bendiksen, Henriette Andresen, Kaja Knudsen Bergo, Emil Knut Espe, Almira Hasic, Ida Marie Hauge‐Iversen, Ioanni Veras, Rizwan I. Hussain, Ivar Sjaastad, Geir Christensen, Alessandro Cataliotti Tags: Original Research Article Source Type: research
The prevalence, predictors, and outcomes of spontaneous echocardiographic contrast or left ventricular thrombus in patients with HFrEF
This study aimed to determine prevalence, predictors, and association with ischaemic stroke risk of spontaneous echocardiographic contrast (SEC) or left ventricular thrombus (LVT) in patients with heart failure with reduced ejection fraction (HFrEF).Methods and resultsClinical, echocardiographic, and follow ‐up data from January 2009 through February 2019 were retrospectively extracted from electronic medical records of patients with heart failure with left ventricular ejection fraction
Source: ESC Heart Failure - January 26, 2021 Category: Cardiology Authors: Xiaodong Zhou, Ruiyu Shi, Gaojun Wu, Qianli Zhu, Changzuan Zhou, Liangguo Wang, Chenglong Xue, Yuanyuan Jiang, Xueli Cai, Weijian Huang, Peiren Shan Tags: Original Research Article Source Type: research
Regression of severe heart failure after combined left ventricular assist device placement and sleeve gastrectomy
AbstractPatients who suffer morbid obesity and heart failure (HF) present unique challenges. Two cases are described where concomitant use of laparoscopic sleeve gastrectomy (LSG) and left ventricular assist device (LVAD) placement enabled myocardial recovery and weight loss resulting in explantation. A 29 ‐year‐old male patient with a body mass index (BMI) of 59 kg/m2 and severe HF with a left ventricular ejection fraction (LVEF) of 20 –25% underwent concomitant LSG and LVAD placement. Sixteen months after surgery, his BMI was reduced to 34 kg/m2 and his LVEF improved to 50 –55%. A second 41‐ye...
Source: ESC Heart Failure - January 24, 2021 Category: Cardiology Authors: Sriram S. Nathan, Pouya Iranmanesh, Igor D. Gregoric, Mehmet H. Akay, Sachin Kumar, Bindu H. Akkanti, Ismael A. Salas de Armas, Manish Patel, Melissa M. Felinski, Shinil K. Shah, Kulvinder S. Bajwa, Biswajit Kar Tags: Case Report Source Type: research
Complications of left ventricular assist devices causing high urgency status on waiting list: impact on outcome after heart transplantation
ConclusionsLeft ventricular assist device therapy can impair the outcome after HTx. However, the occurrence of LVAD complications may not impact on outcome after HTx. Thus, we cannot support the prioritization or discrimination of HTx candidates according to distinct mechanical circulatory support ‐associated complications. Future allocation strategies have to respect that device‐related complications may define urgency but do not impact on the outcome after HTx. (Source: ESC Heart Failure)
Source: ESC Heart Failure - January 21, 2021 Category: Cardiology Authors: Moritz Benjamin Immohr, Udo Boeken, Franziska Mueller, Emir Prashovikj, Michiel Morshuis, Charlotte B öttger, Hug Aubin, Jan Gummert, Payam Akhyari, Artur Lichtenberg, René Schramm Tags: Original Research Article Source Type: research
A clinical score for predicting left ventricular reverse remodelling in patients with dilated cardiomyopathy
This study aimed to assess the clinical predictors of LVRR and establish a scoring system for predicting LVRR in patients with DCM that can be used at any institution.Methods and resultsWe consecutively enrolled 131 patients with DCM and assessed the clinical predictors of LVRR. LVRR was defined as an absolute increase in left ventricular ejection fraction (LVEF) from ≥10% to a final value of>35%, accompanied by a decrease in left ventricular end ‐diastolic dimension (LVEDD) ≥ 10% on echocardiography at 1 ± 0.5 years after a diagnosis of DCM. The mean patient age was 50.1 &pl...
Source: ESC Heart Failure - January 20, 2021 Category: Cardiology Authors: Yuki Kimura, Takahiro Okumura, Ryota Morimoto, Shingo Kazama, Naoki Shibata, Hideo Oishi, Takashi Araki, Takashi Mizutani, Tasuku Kuwayama, Hiroaki Hiraiwa, Toru Kondo, Toyoaki Murohara Tags: Original Research Article Source Type: research